Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.37 |
| ▸ | DDX3X | O00571 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900631 | 0.86 | PDE7A (0.41) | TRPV1P4HTMKCNQ3KCNQ2MAPT | |
| SCHEMBL16246243 | 0.85 | DDX3X (0.38) | P4HTMKCNQ3KCNQ2DDX3XMAPT | |
| SCHEMBL16881120 | 0.81 | P4HTM (0.39) | P4HTMKCNQ3KCNQ2MAPTMEN1 | |
| SCHEMBL17784989 | 0.80 | TRPV1 (0.43) | TRPV1P4HTMDDX3XMAPTGAA | |
| SCHEMBL27961407 | 0.79 | PABPC1 (0.34) | P4HTMKCNQ3KCNQ2DDX3XMAPT | |
| SCHEMBL16423725 | 0.78 | NAMPT (0.39) | P4HTMKCNQ3KCNQ2MAPTMEN1 | |
| SCHEMBL16245958 | 0.77 | NAMPT (0.47) | TRPV1HDAC1HDAC6 | |
| SCHEMBL28813012 | 0.77 | TRPV1 (0.41) | TRPV1P4HTMHSD17B10 | |
| SCHEMBL28723871 | 0.77 | P4HTM (0.34) | P4HTMKCNQ3KCNQ2MAPTGAA | |
| SCHEMBL28292574 | 0.76 | P4HTM (0.41) | TRPV1P4HTMMAPTGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | claimed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | claimed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | claimed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3484878-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | Bristol-Myers Squibb Company (US) | 2019-05-22 | — | — | EP | disclosed |
| CN-109689647-A | The compound that bicyclic heteroaryl replaces | 百时美施贵宝公司 | 2019-04-26 | — | — | CN | disclosed |
| EP-2994470-B1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2018-04-18 | — | — | EP | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
| US-9630963-B2 | Quinolone derivatives as fibroblast growth factor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160130268-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-05-12 | — | — | US | disclosed |
| EP-2994470-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | Principia Biopharma Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| WO-2014182829-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | TRPV1 1398/4885P4HTM 761/4885KCNQ3 2572/4885 |
| US-20160130268-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | TRPV1 4403/4885P4HTM 2664/4885KCNQ3 2779/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | TRPV1 1590/4885P4HTM 1036/4885KCNQ3 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.